These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30197356)

  • 1. Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case series follow-up study.
    Kalyanam B; Sarala N; Azeem Mohiyuddin SM; Diwakar R
    J Cancer Res Ther; 2018; 14(5):1099-1104. PubMed ID: 30197356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R; Ruckenstein MJ; Leake F; Steere E; Robbins KT
    Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for ototoxicity due to cisplatin.
    Blakley BW; Gupta AK; Myers SF; Schwan S
    Arch Otolaryngol Head Neck Surg; 1994 May; 120(5):541-6. PubMed ID: 8172706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
    Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
    BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
    J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
    Colevas AD; Lira RR; Colevas EA; Lavori PW; Chan C; Shultz DB; Chang KW
    Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
    Schuette A; Lander DP; Kallogjeri D; Collopy C; Goddu S; Wildes TM; Daly M; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):106-112. PubMed ID: 31750863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
    Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
    Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
    J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audiometric monitoring of cis-platinum ototoxicity.
    Brown RL; Nuss RC; Patterson R; Irey J
    Gynecol Oncol; 1983 Oct; 16(2):254-62. PubMed ID: 6685094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
    Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
    J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
    Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Verkaik RS; Schornagel JH; Balm AJ; Dreschler WA; Rasch CR
    Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
    Okada H; Kitagawa K
    Cancer Med; 2023 Apr; 12(7):7904-7910. PubMed ID: 36567514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Skalleberg J; Solheim O; Fosså SD; Småstuen MC; Osnes T; Gundersen POM; Bunne M
    Gynecol Oncol; 2017 Apr; 145(1):148-153. PubMed ID: 28202195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
    Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
    J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
    Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
    HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.